Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

13.2K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
13.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.5K
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

174
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
174
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion.

Blood advances·2026
Same author

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

HemaSphere·2026
Same author

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee.

Bone marrow transplantation·2026
Same author

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Bone marrow transplantation·2026
Same author

The Cellular Response Capacity as Diagnostic Head Start in Neutrophil Endotoxemia Sensing.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Reply to Comment on "A new principle to attenuate ischemia-reperfusion injury in kidney transplantation".

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026

Related Experiment Video

Updated: Apr 17, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Dimitrios C Mastellos1, Despina Yancopoulou, Petros Kokkinos

  • 1Division of Biodiagnostic Sciences and Technologies, INRASTES, National Center for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, Greece.

European Journal of Clinical Investigation
|February 14, 2015
PubMed
Summary

Compstatin, a C3 inhibitor, shows promise for treating inflammatory diseases. Drug design efforts have yielded potent analogues with improved pharmacokinetics, demonstrating efficacy in disease models.

Keywords:
Cp40clinical translationcomplement-based drug designcompstatinnonhuman primate modelspeptidic C3 inhibitors

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.4K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Related Experiment Videos

Last Updated: Apr 17, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.4K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Area of Science:

  • Immunology
  • Pharmacology
  • Drug Discovery

Background:

  • The complement system, crucial for innate immunity, is increasingly implicated in various diseases beyond pathogen clearance.
  • Dysregulated complement activation presents therapeutic opportunities for anti-inflammatory drug design.
  • C3 is a central component of the complement cascade, making it an attractive target for therapeutic intervention.

Purpose of the Study:

  • To review the drug design efforts focused on the compstatin family of C3 inhibitors.
  • To highlight promising compstatin drug candidates for clinical applications.
  • To discuss translational challenges and concerns in complement-based drug development.

Main Methods:

  • Rational drug design integrating 'wet' and in silico synthetic approaches.
  • Biophysical, structural, and analytical tools for structure-function refinement.
  • Evaluation of compstatin analogues in primate models of disease.

Main Results:

  • Compstatin analogues exhibit enhanced inhibitory potency and improved pharmacokinetic profiles.
  • Optimized compstatin derivatives demonstrate efficacy in clinically relevant disease models.
  • Significant progress has been made in refining compstatin for therapeutic use.

Conclusions:

  • Compstatin represents a promising therapeutic strategy for modulating complement activation.
  • Further development of compstatin analogues holds potential for treating a wide range of diseases.
  • Addressing translational challenges is key for the successful clinical application of complement inhibitors.